Xintong Wu

Xintong Wu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
WLWenyu Liu
Wenyu Liu
MLMintao Lin
Mintao Lin
QYQiang Yue
Qiang Yue
QGQiyong Gong
Qiyong Gong
DZDong Zhou
Dong Zhou
XWXintong Wu
Xintong Wu

18 June 2024 in Epilepsia Open
Verified
Journal Article
Open access
HZHesheng Zhang
Hesheng Zhang
zhujing Ouzhujing Ou
zhujing Ou
EZEnhui Zhang
Enhui Zhang
WLWenyu Liu
Wenyu Liu
NHNanya Hao
Nanya Hao
XWXintong Wu
Xintong Wu
Objective: Several antiseizure medications (ASMs) have been approved for the treatment of focal epilepsy. However, there is a paucity of evidence on direct comparison of ASMs. We evaluated the comparative efficacy and safety of all approved add‐on ASMs for the treatment of focal epilepsy using network meta‐analysis.Methods: Data through extensive literature search was retrieved from PubMed, Embase, Cochrane, and ClinicalTrial.gov databases using predefined search terms from inception through March 2023. PRISMA reporting guidelines (CRD42023403450) were followed in this study. Efficacy outcomes assessed were ≥50%, ≥75%, and 100% responder rates. Patient retention rate and safety outcomes such as overall treatment‐emergent adverse events (TEAEs) and individual TEAEs were assessed. “Gemtc” 4.0.4 package was used to perform Bayesian analysis. Outcomes are reported as relative risks (RRs) and 95% confidence interval (CI).Results: Literature search retrieved 5807 studies of which, 75 studies were included in the analysis. All ASMs showed significantly higher ≥50% responder rate compared with placebo. Except the ≥75% seizure frequency reduction for zonisamide (2.23; 95% CI: 1.00–5.70) and 100% for rufinamide (2.03; 95% CI: 0.54–11.00), all other interventions showed significantly higher ≥75% and 100% responder rates compared with placebo. Among treatments, significantly higher 100% responder rate was observed with cenobamate compared to eslicarbazepine (10.71; 95% CI: 1.56–323.9) and zonisamide (10.63; 95% CI: 1.37–261.2). All ASMs showed a lower patient retention rate compared to placebo, with the least significant value observed for oxcarbazepine (0.77; 95% CI: 0.7–0.84). Levetiracetam showed a lower risk of incidence (1.0; 95%CI: 0.94–1.1; SUCRA: 0.885067) for overall TEAE compared with other medications.Significance: All approved ASMs were effective as add‐on treatment for focal epilepsy. Of the ASMs included, cenobamate had the greatest likelihood of allowing patients to attain seizure freedom.Plain Language Summary: This article compares the efficacy and safety of antiseizure medications (ASMs) currently available to neurologists in the treatment of epileptic patients. Several newer generation ASMs that have been developed may be as effective or better than the older medications. We included 75 studies in the analysis. In comparison, all drugs improved ≥50%, ≥75% and 100% responder rates compared to control, except for Zonisamide and Rufinamide in the ≥75% and 100% responder rate categories. Retention of patients undergoing treatment was lower in drugs than placebo. All drugs were tolerated, the levetiracetam showed the best tolerability. Cenobamate more likely help completely to reduce seizures.

Verified
Journal Article
Open access
PDF file
YCYujie Chen
Yujie Chen
zhujing Ouzhujing Ou
zhujing Ou
DZDong Zhou
Dong Zhou
XWXintong Wu
Xintong Wu
Artificial intelligence (AI) has emerged as a transformative tool in the analysis and management of epilepsy through its integration with electroencephalography (EEG) data. The adoption of AI-assisted solutions in managing epilepsy holds the potential to significantly enhance the efficiency and accuracy for diagnosing this complex condition. However, AI-assisted EEG technologies are infrequently adopted in clinical settings. In this Review, we provide an overview of AI applications in seizure prediction, detection, syndrome classification, surgical planning, and prognosis prediction. Additionally, we explore the methodological considerations and challenges that are relevant in clinical settings. Overall, AI has the potential to revolutionize epilepsy management, ultimately improving patient outcomes and advancing the field of precision medicine. Fostering interdisciplinary collaborations between AI researchers, neurologists, and ethicists will be crucial in creating integrated solutions that address both technical and clinical requirements.

1 July 2021 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
WLWenyu Liu
Wenyu Liu
QYQiang Yue
Qiang Yue
QGQiyong Gong
Qiyong Gong
DZDong Zhou
Dong Zhou
XWXintong Wu
Xintong Wu
Background: Focal epilepsy accounts for most epilepsy cases, and frontal lobe epilepsy (FLE) accounts for the largest proportion of cases of extratemporal epilepsy syndrome. The epileptogenic zone is usually not easy to locate, contributing to a lack of imaging studies. The objective of this study was to evaluate functional connectivity patterns to explore the underlying pathological mechanisms of this disorder. Methods: Forty-three patients with focal extratemporal epilepsy [mean age ± standard deviation (SD): 29.51±8.04 years, 19 males] and the same number of healthy controls (mean age ± SD: 29.56±8.02 years, 19 males) were recruited to undergo functional magnetic resonance imaging. Mean regional homogeneity (ReHo) was measured, and regions showing significant alterations in ReHo in patients were identified to examine functional connectivity (FC). In particular, FC within the default mode network (DMN) in patients was analyzed. Results: Patients with extratemporal lobe epilepsy showed significantly higher ReHo in the bilateral precentral gyrus, and lower ReHo in frontal-cerebellum regions than healthy controls [P<0.05, Gaussian random field (GRF)-corrected]. FC analysis based on regions of interest showed significantly higher connectivity in the frontoparietal-insula region and lowered FC in the frontal-cerebellum regions (P<0.05, GRF-corrected). Altered FC within DMN was also demonstrated (P<0.05, GRF-corrected). Conclusions: Analyses of ReHo and FC based on regions of interest suggest epilepsy-related neural networks are located mainly in frontal regions in extratemporal lobe epilepsy. These findings reveal disruptions of interactions and connectivity of large-scale neural networks and frontotemporal-cerebellar regions, suggesting connectivity-based pathophysiology.

12 April 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
HZHesheng Zhang
Hesheng Zhang
WXWeixi Xiong
Weixi Xiong
XLXu Liu
Xu Liu
WLWenyu Liu
Wenyu Liu
DZDong Zhou
Dong Zhou
XWXintong Wu
Xintong Wu
Objective: This study aimed to evaluate the clinical characteristics and long-term surgical outcomes of patients with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis with teratoma.Methods: Patients who were admitted to West China Hospital from June 2012 to June 2019 and diagnosed with anti-NMDAR encephalitis were enrolled in the study. Medical records were reviewed prospectively to gather clinical characteristic data. Patients were followed up at long-term every 3 months.Results: This study included 192 patients, among whom 21 (10.9%) were detected with having a teratoma. Patients included 20 women, with a mean age of 24.62 ± 7.61 years. Seizure and psychiatric symptoms were the most dominant symptoms in both groups, followed by memory deficits. Central hypoventilation (52.4 vs. 17%, p < 0.001) and decreased consciousness (71.4 vs. 31.3%, p = 0.002) were significantly more frequent in patients with teratoma than in those without. Moreover, the anti-NMDAR antibody titer was higher (p = 0.021) and the baseline modified Rankin scale score was lower (p = 0.004) in patients with teratoma than in those without. First-line immunotherapy was performed in 21 (100%) patients with teratoma and 167 (97.7%) patients without teratoma. All patients with teratoma had the tumor removed. During follow-up, two (9.5%) patients with teratoma and 11 (6.4%) patients without teratoma died, whereas 1 (4.8%) patient with teratoma and 37 (21.6%) patients without teratoma had relapses. Overall, 19 (90.5%) patients with teratoma and 151 (88.3%) patients without teratoma achieved favorable clinical outcomes at the final follow-up.Conclusions: With early detection and removal of teratoma, most patients with anti-NMDAR encephalitis and teratoma achieved a favorable long-term prognosis.

25 October 2023 in European Journal of Neurology
Verified
Journal Article
Open access
LLLu Lu
Lu Lu
LCLei Chen
Lei Chen
PWPeiyu Wang
Peiyu Wang
ZQZhang Qi
Zhang Qi
YCYujie Chen
Yujie Chen
WXWeixi Xiong
Weixi Xiong
Background and purpose: The aim was to investigate the neurological complications associated with coronavirus disease 19 (COVID‐19) during the 2022 Omicron wave.Methods and analysis: The medical records of a cohort of people admitted to neurological wards of three participating tertiary centres in Sichuan from 12 December 2022 to 12 January 2023 were reviewed. Demographics and clinical data were obtained and analysed with an interest in COVID‐19‐related new‐onset or worse neurological symptoms. The current data were also compared in two centres with similar data from the same period 12 months earlier.Results: In all, 790 people were enrolled, of whom 436 were positive for COVID‐19. Ninety‐nine had new onset COVID‐related neurological problems, or their known neurological condition deteriorated during the wave. There was a significant difference in demographics from the findings amongst admissions 12 months earlier as there was an increase in the average age, the incidence of encephalitis and encephalopathy, and mortality rates. One hundred and one received COVID‐specific antivirals, intravenous glucocorticoids and intravenous immunoglobulin therapy. No differences were seen between these and those who did not use them.Conclusion: New‐onset neurological conditions, particularly encephalitis and encephalopathy, increased significantly during this period. Deterioration of existing neurological conditions, such as seizure exacerbation, was also observed. A large‐scale treatment trial of people with COVID‐19 infection presenting with neurological disorders is still needed.